Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 - a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData.
Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 - a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData.
After acquiring Warner Chilcott for $5 billion last year, and with the acquisition of New York-based Forest Laboratories already one of this year’s largest deals, the Allergan purchase “further cement[s] Actavis’ unwavering growth plans,” says Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics. The total outlay for the three deals comes in at just under $100 billion, “an incredible level of investment undoubtedly triggered by the financial cushion afforded by Actavis’ inversion maneuver to Ireland…”
Owide adds that the Allergan deal “represents a huge premium, heavily dependent on financial engineering”. But synergies within research and development and selling, and general and administrative expenses, could deliver an extra $17 billion in additional cash flows”.
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
February 7th 2025Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson disease.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.